How Trade War 2.0 Benefits Struggling Cronos Stock

As things stand now, cannabis firm Cronos Group (NASDAQ:CRON) is a two-faced investment. CRON stock recovered well from late last year’s volatility, as CRON stock is up nearly 49% since the beginning of January. But Cronos stock shed 30% since March 1, putting a sour taste in recent buyers’ mouths.

Source: Shutterstock

Fundamentally, Cronos has the same split personality. Last week, the company reported its first-quarter  results. On paper, Cronos delivered a strong beat. Analysts’ consensus estimate pegged earnings per share at a loss of two cents. Instead, EPS came in at 36 cents on the positive end of the scale.

Moreover, Cronos rang up 6.47 million CAD, or $4.8 million, of net sales. That was a massive 120% increase from the year-ago quarter. But as The Motley Fool’s Sean Williams noted, the cannabis firm benefited from multiple one-off events. All things considered Cronos Group loses money on its operations.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips

InvestorPlace Managing Editor John Kilhefner has also joined in on the fun. Kilhefner bought CRON stock because, in his words, he was “greedy.” He wanted a “quick short-term boost” and what better place to get that than with marijuana?

• 6 Chinese Stocks That Could Pop On a Trade Deal

However, Kilhefner now regrets buying Cronos stock. For one thing, after clearing his thoughts, he doesn’t view marijuana as an investment but rather, pure speculation. More critically, the reality of cannabis hasn’t come anywhere close to the hype. For instance, Canadian cannabis stores are selling fewer botanical products than previously anticipated.

With that negative backdrop, it’s no wonder why investors are have mixed views on CRON stock. Still, I think Kilhefner and others may want to consider another massive catalyst: China.

CRON Stock Has Received a Massive Tailwind

One of the more surprising developments in geopolitics recently is that the trade war is back on. For weeks, it appeared that the Trump administration and its Chinese counterpart were ready to make a deal.

But the deal appears to have fallen through. This latest freeze in U.S.-China relations may not thaw for quite some time. As InvestorPlace’s William Roth explained, our military exercises in the South China Sea appeared to have been carefully orchestrated.

What does that have to do with CRON stock? Everything. Trump  has pushed himself  into a corner economically. The initial round of tariffs already hurt many businesses across multiple sectors. With the President threatening even harsher penalties, astute market observers are bracing themselves for a rough landing.

Of course, one sector that has absorbed substantial damage is agriculture. Already weakened from demographic challenges,  American farmers have been put in a vice grip by tariffs. Since much of this country’s agricultural base is located in conservative regions, Trump can’t play hardball with the Chinese without incurring political penalties.

That is where CRON stock and other major marijuana names like Canopy Growth (NYSE:CGC) and Aurora Cannabis (NYSE:ACB) come into the picture. If this “trade war 2.0” worsens – again, Roth forwarded evidence that it will – full recreational legalization is on the table.

Despite growing political momentum, getting rid of the federal government’s Schedule I classification appeared to be a pipe dream. Even during the Obama administration, marijuana tip-toed a delicate balance between states’ rights and federal oversight.

But right now, there’s a good chance that our economy will enter a recession. Trump will  either have to give in to the Chinese or make concessions on the cannabis legalization front. I’d say that’s a long-term benefit to CRON stock.

Don’t Give Up on Cronos Stock!

If Kilhefner hasn’t dumped his shares of Cronos Group stock, I’d recommend he bite the bullet and wait. Politically, what’s currently happening is the best thing ever for the marijuana industry.